Who we are

Latin America is still lacking regulatory harmonization that extends across its 20 member countries. There are some regional and sub-regional initiatives to promote regulatory convergence, but work is still ongoing and the stage of maturity of the regulatory system varies significantly from country to country. The region presents a challenge for global drug companies, leading to longer approval timelines and a bigger strain on resources. In order to succeed in LATAM the pharma industry must balance its global expertise and systems while addressing country specific requirements and regulatory nuances.

PharmaLex in the LATAM region operates using a mixed/combined model, with own offices in the regions most important markets, coupled/paired with a long-established partnership with an expert local service provider RAFINT (Regulatory Affairs International S.A.C.)*.  Our partnership model ensures that PharmaLex can offer the full PharmaLex portfolio of products and services and using our central corporate operating system. This safeguards PharmaLex’s high-quality standards whilst at the same time enabling us to expand our products and services into new territories across the globe.

Covering countries including: Brazil, Mexico, Colombia, Peru, Argentina, Ecuador, Venezuela, Bolivia, Chile, Paraguay and Central American & Caribbean countries. PharmaLex LATAM has well-established local representatives with broad experience across the region. Their local expertise enables them to successfully navigate the regulatory landscape in each country, including significant experience in meeting with the local Health Authorities, such as DIGEMID (Peru) and COFEPRIS (Mexico).

____________

*RAFINT offers the core PharmaLex services specializing in regulatory affairs, including regulatory intelligence, maintenance, clinical trial applications and marketing authorization approvals. Supporting our existing LATAM operations, RAFINT seamlessly complements the PharmaLex portfolio offering our clients good value for money as well as confidence that their requirements will be met.

Local Contact

  • Fátima Monteiro
    Manager, Regulatory Affairs
Download Terms and Conditions

What our clients say about us

We are working with a number of large pharma companies and are looking to create a consortium of partners to collect feedback on expertise, availability and outcomes. If you would be interested in joining our consortium, please contact us on contact@pharmalex.com.

  • I just wanted to relay our sincere thanks to you and the team for two really excellent days training. It was well organized and structured to cover regulatory expectations, GMP principle and routine work challenges of industry. The presenters and moderator were highly skilled in this area to accommodate any queries raised during the training session and were well able to keep the team engaged even in remote/virtual training session. The design of training slides was impressive and the use of technology to make virtual training was remarkable.

    Lorraine Henry
    Compliance Lead, Qualified Person, Amneal Ireland Limited

  • Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team

    US based large development group
    VP Regulatory / Quality

  • I just wanted to let you know that the recent EU Codes webinar was excellent. Rina presented a very complex and grey topic in the most clear and digestible manner – a sign of a true expert. The questions in the Q&A were sometimes a little ambiguous but Rina gave clear and relevant answers that provided real clarity.

    Richard Blackwell
    Medical Team Leader, Multi Tumor Franchise Roche Products Ltd

  • We needed a partner to help us obtain device approval. PharmaLex have not only helped us achieve this but are now providing on-going post-marketing surveillance support. We would highly recommend them to anyone who needs specialist expertise.

    Med Device company, US
    Senior Regulatory Affairs Director

Related News